Table 4.
Abnormal laboratory values: patients with at least one occurrence per grade
| Category | HCC | ICC | mCRC | Other mets (248) | Total (1027) |
|---|---|---|---|---|---|
| Patients with at least 1 abnormal laboratory value | 359 (85.1) | 96 (80) | 158 (66.7) | 179 (72.2) | 792 (77.1) |
| Patients with at least 1 grade ≥ 3 abnormal laboratory value | 129 (30.6) | 27 (22.5) | 42 (17.7) | 47 (19) | 245 (23.9) |
| Albumin decreased—grade | |||||
| n | 422 | 120 | 237 | 248 | 1027 |
| 1 | 167 (39.6) | 26 (21.7) | 36 (15.2) | 47 (19) | 276 (26.9) |
| 2 | 117 (27.7) | 25 (20.8) | 29 (12.2) | 38 (15.3) | 209 (20.4) |
| 3 | 19 (4.5) | 4 (3.3) | 9 (3.8) | 2 (0.8) | 34 (3.3) |
| ALT increased—grade | |||||
| n | 422 | 120 | 237 | 248 | 1027 |
| 1 | 197 (46.7) | 49 (40.8) | 80 (33.8) | 106 (42.7) | 432 (42.1) |
| 2 | 31 (7.3) | 2 (1.7) | 15 (6.3) | 20 (8.1) | 68 (6.6) |
| 3 | 13 (3.1) | 0 (0) | 9 (3.8) | 6 (2.4) | 28 (2.7) |
| 4 | 0 (0) | 0 (0) | 0 (0) | 1 (0.4) | 1 (0.1) |
| AST increased—grade | |||||
| n | 422 | 120 | 237 | 248 | 1027 |
| 1 | 258 (61.1) | 55 (45.8) | 108 (45.6) | 118 (47.6) | 539 (52.5) |
| 2 | 66 (15.6) | 12 (10) | 24 (10.1) | 23 (9.3) | 125 (12.2) |
| 3 | 25 (5.9) | 3 (2.5) | 13 (5.5) | 14 (5.6) | 55 (5.4) |
| 4 | 3 (0.7) | 0 (0) | 0 (0) | 1 (0.4) | 4 (0.4) |
| Bilirubin increased—grade | |||||
| n | 422 | 120 | 237 | 248 | 1027 |
| 1 | 154 (36.5) | 24 (20) | 57 (24.1) | 44 (17.7) | 279 (27.2) |
| 2 | 141 (33.4) | 22 (18.3) | 35 (14.8) | 34 (13.7) | 232 (22.6) |
| 3 | 63 (14.9) | 15 (12.5) | 19 (8) | 20 (8.1) | 117 (11.4) |
| 4 | 18 (4.3) | 3 (2.5) | 6 (2.5) | 7 (2.8) | 34 (3.3) |
| INR increased | |||||
| n | 422 | 120 | 237 | 248 | 1027 |
| 1 | 133 (31.5) | 17 (14.2) | 38 (16) | 26 (10.5) | 214 (20.8) |
| 2 | 57 (13.5) | 10 (8.3) | 16 (6.8) | 14 (5.6) | 97 (9.4) |
| 3 | 14 (3.3) | 1 (0.8) | 1 (0.4) | 3 (1.2) | 19 (1.9) |
| Neutrophil count decreased—grade | |||||
| n | 422 | 120 | 237 | 248 | 1027 |
| 1 | 36 (8.5) | 14 (11.7) | 8 (3.4) | 16 (6.5) | 74 (7.2) |
| 2 | 22 (5.2) | 5 (4.2) | 7 (3) | 8 (3.2) | 42 (4.1) |
| 3 | 6 (1.4) | 1 (0.8) | 5 (2.1) | 11 (4.4) | 23 (2.2) |
| 4 | 0 (0) | 1 (0.8) | 1 (0.4) | 1 (0.4) | 3 (0.3) |
| Platelet count decreased—grade | |||||
| n | 422 | 120 | 237 | 248 | 1027 |
| 1 | 216 (51.2) | 55 (45.8) | 58 (24.5) | 78 (31.5) | 407 (39.6) |
| 2 | 73 (17.3) | 17 (14.2) | 10 (4.2) | 10 (4) | 110 (10.7) |
| 3 | 27 (6.4) | 5 (4.2) | 1 (0.4) | 5 (2) | 38 (3.7) |
| 4 | 5 (1.2) | 1 (0.8) | 2 (0.8) | 1 (0.4) | 9 (0.9) |
Data are presented as n (%)
ALT Alanine transaminase, AST Aspartate aminotransferase, ICC intrahepatic cholangiocarcinoma, INR International Normalised Ratio, HCC hepatocellular carcinoma, mCRC metastatic colorectal cancer, TARE transarterial radioembolization